AHL
OVID icon

Abel Hall LLC’s Ovid Therapeutics OVID Stock Holding History

Abel Hall LLC’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76.2K Sell
28,324
-2,865
-9% -$7.39K 0.01% 867
2026
Q1 		$69.2K Sell
31,189
-238
-0.8% -$426 0.01% 718
2025
Q4 		$51.2K Sell
31,427
-921
-3% -$1.42K 0.01% 658
2025
Q3 		$42.1K Hold
32,348
– – 0.02% 302
2025
Q2 		$10.7K Buy
32,348
+22,110
+216% +$6.66K ﹤0.01% 282
2025
Q1 		$3.19K Buy
+10,238
New +$6.29K ﹤0.01% 201

Other funds holding OVID

PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
SFG
Sovereign Financial Group Stamford, Connecticut $654M AUM 32.34% 1-Year Est. Return
TCWM
Total Clarity Wealth Management St. Charles, Illinois $515M AUM 27.37% 1-Year Est. Return
BMC
Benin Management Corp Wilton, Connecticut $494M AUM 25.95% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
AWA
Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return
TFM
TFC Financial Management Boston, Massachusetts $902M AUM 21.74% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return

Abel Hall LLC's OVID Position: Q2 2026 in Review

Abel Hall LLC reduced its Ovid Therapeutics (OVID) stake by 9.2% in Q2 2026, selling an estimated $7.39K and leaving 28,324 shares worth $76.2K. The position accounts for 0.01% of the portfolio, ranked #867.

Abel Hall LLC first reported a position in OVID in Q1 2025 and has held it in 6 quarters since. 13 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Abel Hall LLC held 28,324 shares of Ovid Therapeutics worth $76.2K as of Q2 2026.
  • Abel Hall LLC sold 2,865 Ovid Therapeutics shares in Q2 2026, an estimated $7.39K.
  • Ovid Therapeutics made up 0.01% of Abel Hall LLC's portfolio in Q2 2026, its #867 holding.
  • Abel Hall LLC first reported a position in Ovid Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 13 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.